Testing effectiveness (Phase 2)Looking for participantsNCT05832827
What this trial is testing
First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)
Who this might be right for
Untreated Advanced or Recurrent Thymic Carcinomas
National Cancer Center, Japan 35